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IL-17B is a member of the IL-17 cytokine family which have been implicated in inﬂammatory response and autoimmune diseases
such as rheumatoid arthritis. The founding member of this family, IL-17 (or IL-17A), has also been implicated in promoting
tumour angiogenesis through the induction of other proangiogenic factors. Here we examine the potential of recombinant human
IL-17B to contribute to the angiogenic process. In vitro rhIL-17B was able to inhibit HECV endothelial cell-matrix adhesion and
cellular migration and also, at higher concentrations, could substantially reduce tubule formation compared to untreated HECV
cells in a Matrigel tubule formation assay. This data suggests that IL-17B may act in an antiangiogenic manner.
1.Introduction
IL-17, initially termed CTLA-8, was identiﬁed in 1993
through subtractive hybridisation of a rodent cDNA library
and was found to share homology to the ORF13 gene of the
Herpesvirus saimiri. Subsequent studies identiﬁed both the
receptor for IL-17/CTLA-8 cytokine and the human version
of IL-17. IL-17 has been shown to induce IL-6 and IL-8
production together with enhanced expression of ICAM-
1a n dN F - κBa c t i v i t y[ 1–3]. Since their initial discovery,
research into the IL-17 cytokine family has identiﬁed six
members, IL-17 (IL-17A) -IL-17F, which signal through a
familyofIL-17receptors,IL-17RA–IL-17RE(reviewedinfull
in [4, 5]).
IL-17 can cause the induction of proinﬂammatory
factors, contributing to the immune response. However this
cytokine has also been shown to play a role in autoimmune
disorders such as rheumatoid arthritis [6–9]. Various studies
have also investigated the role of IL-17 in cancer progression,
discovering that IL-17 possesses both anti- and pro tumour
roles. IL-17-transfected haematopoietic tumours grafted
onto syngeneic immunocompetent mice grew at a signiﬁ-
cantly reduced rate to mock transfected control tumours and
this reduction was associated with the enhanced generation
of CTLs [10]. Another study suggests that endogenous
IL-17 may be involved in tumour immunity and show
that MC38 colon cancer cells inoculated subcutaneously
developed signiﬁcantly faster in IL-17-deﬁcient mice than
wild-type mice and developed signiﬁcantly more metastatic
foci than wild-type mice following intravenous injection of
MC38 [11]. The protumorigenic eﬀects of IL-17 seem largely
due to its ability to contribute to the inﬂammatory response
and enhance angiogenesis. IL-17-transfected tumour cells
have been shown to enhance in vivo growth and show
signiﬁcantly enhanced tumour vascularity compared to
control cells, whilst in vitro IL-17 treatment stimulated
vascular endothelial cell migration and cord formation and
caused upregulation of a number of proangiogenic factors
in ﬁbroblasts and tumour cells [12]. Subsequent work has
shown that IL-17 could enhance HGF-, VEGF-, and bFGF-
induced vascular endothelial cell growth and thus may help
to mediate angiogenesis promoted through these growth
factors [13]. Elevated levels of serum IL-17 have been
detected in multiple myeloma patients, with levels being
signiﬁcantly higher in stage II and III patients than in stage I
patients and in these patients serum IL-17 levels were found
to correlate positively with levels of VEGF, TNFα,a n dm i c r o
vessel density [14].2 Journal of Oncology
Currently there are few studies focusing on the IL-17B
member of the IL-17 cytokine family in cancer progression
and angiogenesis. IL-17B was initially cloned and charac-
terisedin2000[15].IL-17Bsharesapproximately27%amino
acid identity with IL-17, has a wider expression pattern with
transcripts being demonstrated in human adult pancreas,
small intestine, stomach, and testis, and can stimulate the
release of tumour necrosis factor alpha (TNFα)a n dI L - 1 β
in the THP-1 monocytic cell line [15]. IL-17B has also been
suggestedtoplayanimportant roleininﬂammatoryarthritis
[16]. In the current study we use rhIL-17B to assess the role
of IL-17B in the human HECV endothelial cell line and its
potential to impact on traits, such as cellular migration and
tubule formation, associated with the angiogenic process.
2.Methodology
2.1. Reagents, Cell Lines, and Culture Conditions. The human
HECVendothelialcelllinewaspurchasedfromtheEuropean
Collection of Animal Cell Cultures (ECACC, Salisbury,
UK). Cells were routinely subcultured in Modiﬁed Eagle
Medium (DMEM) (PAA Laboratories Ltd., Somerset, UK)
supplemented with 10% Fetal Bovine Serum (PAA Labo-
ratories Ltd, Somerset, UK), penicillin, and streptomycin.
The cells were maintained in an incubator at 37◦Ca n d5 %
CO2 humidity. Recombinant human IL-17B (rhIL-17B) was
purchased from R&D systems (Abingdon, UK).
2.2. Cell Function Assays
2.2.1. In Vitro Cell Growth Assay. The impact of rhIL-17B
on HECV cell growth was assessed using an in vitro cell
growth assay. Cells were seeded into a 96-well plate at a
seeding density of 3,000 cells/well and treated with a range
of rhIL-17B concentrations (0ng/mL, 10ng/mL, 50ng/mL,
100ng/mL, and 250ng/mL). Triplicate plates were set up
and incubated for periods of overnight, 3 days or 5 days.
Following incubation, the medium was removed; cells were
ﬁxed in 4% (v/v) formalin for 5 minutes, stained in 0.5%
(w/v) crystal violet for 5 minutes, and rinsed. The crystal
violet stain taken up by the cells was then extracted in a 10%
(v/v) acetic acid solution and cell growth was determined
spectrophotometrically using a Bio-Tek ELx800 multiplate
reader (Bio-Tek Instruments Inc., Vermont, USA).
2.2.2. In Vitro Matrigel Adhesion Assay. The impact of rhIL-
17B on HECV cell-matrix adhesion was assessed using an
in vitro Matrigel adhesion assay previously described [17].
In brief, wells of a 96-well plate were precoated with 5μg
of Matrigel (BD Biosciences, Oxford, UK) before seeding
30,000 HECV cells in medium containing a range of rhIL-
17B concentrations (0ng/mL control, 10ng/mL, 50ng/mL,
and 100ng/mL). Cells were incubated for 45 minutes before
being subjected to intense washing to remove nonadherent
cells,ﬁxedin4%(v/v)formalin,andstainedwith0.5%(w/v)
crystal violet. Adherent cells were subsequently observed
under a microscope and the number of adherent cells per
ﬁeld were calculated in a number of random ﬁelds.
2.2.3. In Vitro Migration/Wounding Assay. Am i g r a t i o n /
wounding assay was used to assess the impact of rhIL-17B
on HECV cellular migration. This protocol was modiﬁed
from a previously described method [18]. Brieﬂy, cells were
culturedina24-wellplateuntiltheyreachedanearconﬂuent
monolayer. This monolayer was subsequently scratched with
a 21G needle and the medium was replaced with fresh
medium containing a range of concentrations of rhIL-17B
(0ng/mL control, 10ng/mL, 50ng/mL, and 100ng/mL).
Cellular migration from the two wound fronts was tracked
and recorded over a 90-minute period using a time-lapse
video recorder (Panasonic, Japan). Migration rates were
those calculated at 15 minute-time intervals within the 90-
minute period using Optimas 6 motion analysis software.
2.2.4. In Vitro Matrigel Tubule Formation Assay. Matrigel
endothelial cell tube formation assays were set up to assess
any impact on angiogenic eﬀect following treatment with
rhIL-17B at a range of concentrations (0ng/mL, 10ng/mL,
50ng/mL, 100ng/mL, and 250ng/mL). The protocol used
was modiﬁed from that previously reported [19]. Brieﬂy,
250μg of Matrigel was seeded into a 96-well plate in serum-
free medium and left to gel in an incubator for a minimum
of 40 minutes. Once the Matrigel had set, 30,000 HECV
cells were seeded onto the Matrigel layer and incubated for
4-5 hours to allow tubule formation to occur. Following
incubation, any tubules that had formed were visualized
under low magniﬁcation and images captured. Total tubule
perimeter/ﬁeld in these images were later quantiﬁed using
ImageJ software.
2.3. Statistical Analysis. All experimental procedures were
repeated a minimum of three independent times. Data was
analysed using Minitab 14 statistical package using a two-
sample two-tailed t-test to compare treated samples to that
of untreated controls. Values of P<. 05 were taken as being
statistically signiﬁcant.
3. Results and Discussion
3.1. rhIL-17B Had Little Impact on HECV Cell Growth over
a Range of Concentrations. rhIL-17B was added to the cells
at concentrations of 10ng/mL, 50ng/mL, 100ng/mL, and
250ng/mL and the growth rates were compared to those
an untreated control in order to determine the toxicity of
rhIL-17B. Treatment of HECV cells with rhIL-17B seemed
to have little eﬀect on the growth rate of this cell line over
the incubation period and concentrations tested (Figure 1).
Following 3-day incubation at the various treatments, there
is very little variation between the growth rates of the treated
cellsandtheuntreatedcontrolcells.Followingalonger5-day
treatment of HECV cells with rhIL-17B, a noticeable drop
in growth can be seen in the highest tested concentration
of 250ng/mL; however all other treatment concentrations
show little variability in growth rates compared to untreated
control HECV cells. No signiﬁcant diﬀerence was observed
at any concentration at any speciﬁc incubation period when
compared to the untreated control of the same incubationJournal of Oncology 3
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Figure 1: HECV growth was not aﬀected by rhIL-17B treatment.
No signiﬁcant diﬀerence in HECV growth rate was observed
following 3- or 5-day incubation periods between the untreated
(0ng/mL) control and any other rhIL-17B treatment concentration
(10ng/mL, 50ng/mL, 100ng/mL, and 250ng/mL).
period. This suggests that IL-17B, at the tested concentra-
tions, does not play a signiﬁcant role in the regulation of cell
growth in the HECV human endothelial cell line.
3.2. rhIL-17B Negatively Impacted on HECV Cell-Matrix
Adhesion and Migration. Treatment of HECV endothe-
lial cells with rhIL-17B could inﬂuence both cell-matrix
adhesion (Figure 2(a)) and cellular migration (Figure 2(b)).
Lower concentrations of rhIL-17B (10ng/mL and 50ng/mL)
had minimal eﬀect on these two traits; however at the higher
concentration of 100ng/mL a signiﬁcant reduction in both
cell-matrix adhesion and cellular migration in comparison
to untreated control HECV cells was noticed. Treatment of
HECV cells with 100ng/mL rhIL-17B reduced the capacity
of the cells to adhere to an artiﬁcial Matrigel basement
membrane (P = .004). Similarly, at this concentration,
rhIL-17B signiﬁcantly reduced cell migration over a 90-
minute period where the migration rates of cells treated
with 100ng/ml rhIL-17B were signiﬁcantly lower than those
of the untreated control cells after 75 minutes (P = .048)
and at the experimental endpoint of 90 minutes (P =
.027). Thus, it appears that IL-17B, at higher concentrations,
may play a role in regulating HECV cell-matrix adhesion
and cell migration. A previous study has investigated the
role of IL-17 in endothelial cell migration in vitro, using a
modiﬁed Boyden chamber assay system, and demonstrated
ap r o m o t i o n a le ﬀect of IL-17 on endothelial cell migration
[12]. Our study examined the impact of rhIL-17B on
endothelial cell migration using a wounding cell migration
system, and whilst diﬀering methodology makes it diﬃcult
to draw direct comparisons between IL-17 and IL-17B, our
results indicate a potential role for IL-17B in the migration
of HECV endothelial cells.
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Figure 2: (a) Eﬀect of rhIL-17B on HECV cell-matrix adhesion.
A signiﬁcant reduction in cell-matrix adhesion was observed
following treatment with 100ng/mL rhIL-17B. (b) Eﬀect of rhIL-
17B on HECV cell migration. Similarly, 100ng/mL rhIL-17B
signiﬁcantly inhibited HECV cell migration and a signiﬁcant
diﬀerence compared to the untreated control in migration was
observed following 75- and 90-minute periods.
∗P <. 05;
∗∗P <
.01.
3.3. rhIL-17B Can Reduce HECV Tubule Formation. Untreat-
ed HECV endothelial cells formed tubule-like structures
when seeded onto Matrigel demonstrating their angiogenic
potential. Treatment of these cells with rhIL-17B adversely
aﬀected the capability of this cell line to form these tubule
structures (Figure 3). This adverse eﬀect was most notable
at the highest concentration of 250ng/mL where, following
quantiﬁcation of tubule perimeter, a signiﬁcant decrease in
tubules was observed in comparison to untreated control
cells (P = .023). Whilst a signiﬁcant reduction in tubule
formation was only observed at the 250ng/mL concentra-
tion, there does appear some marginal eﬀects, following
quantiﬁcation, of rhIL-17B on HECV tubule formation at
100ng/mL and possibly even at 50ng/mL, where mean total
perimeter length/ﬁeld was generally reduced in comparison
totheuntreatedcontrol,thoughboth ofthesetreatmentsdid
not reach signiﬁcance. Thus, this data suggests that IL-17B
may negatively impact on the angiogenesis process through
inhibiting formation of new vessels. This role for IL-17B4 Journal of Oncology
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Figure 3: rhIL-17B inhibited HECV endothelial cell tubule formation. (a) Representative pictures of tubule formation following incubation
with varying concentrations of rhIL-17B. (b) Histogram representing mean quantiﬁed total tubule length per ﬁeld. A signiﬁcant reduction
was observed following treatment with 250ng/mL rhIL-17B.
∗P <. 05.
seems to be in contrast with the proangiogenic eﬀect of IL-
17 observed by Numasaki et al., whose study demonstrated
the capacity of IL-17 to enhance vascular endothelial cell
cord formation over a range of concentrations in vitro and
promote increased tumour vascularity in in vivo models
[12]. In this study Numasaki et al. showed an enhancement
of microvessel development at 50–500ng/mL IL-17 concen-
trations. Whilst our study also tested a range of rhIL-17B
concentrations, signiﬁcant result were only observed at the
higher dose (250ng/mL) and little eﬀect was observed at our
lowest tested concentration of 10ng/mL. However, IL-17B
and its anti-angiogenic actions are not alone in the family.
Other members of the IL-17 family have also been suggested
to have anti-angiogenic inﬂuences at higher concentrations
and an anti-angiogenic role for IL-17F was seen in a study by
Starnes et al., which demonstrated the capacity of IL-17F to
inhibit capillary tubule formation in an in vitro endothelial
cell capillary tubule formation assay at concentrations of
100, 375, and 750ng/mL [20]. Exerting biological functions
at a higher concentration appears to be a common feature
for the IL-17 family members. Another example is IL-17D,
which has signiﬁcant eﬀects at a concentration range of 500–
1000ng/mL [21]. Thus, our data implies that IL-17B may
function diﬀerently to IL-17 in angiogenesis or may itself not
be acting as an independent angiogenic factor. Additionally,
the high concentrations needed to bring about signiﬁcant
eﬀects in vitro may limit the usefulness of IL-17B in vivo
where physiological concentrations of this cytokine are likely
to be substantially lower. Further investigation into both the
mode of action of IL-17B together with additional studies
examining the eﬃcacy and toxicity of IL-17B over a range
of concentration in vivo are required to fully realise the
potential of this cytokine.
4. Conclusions
The data presented suggests that IL-17B may negatively
impact on the angiogenic process through its ability to
inhibit endothelial cell migration and tubule formation
whilst having little eﬀect on endothelial cell growth. Thus,
it appears as though IL-17B could play an opposite role
to that of IL-17 in the angiogenic process which, whilst
also having little eﬀect on endothelial cell proliferation,
promoted endothelial cell migration and tubule formation
[12],thoughdirectcomparisonsbetweenthesetwocytokines
using similar methodologies are required to identify any
contrasting roles. As far as the authors are aware, this data
is the ﬁrst implicating a role for IL-17B in the angiogenesis
process. Additional work is required to fully investigate and
establish the eﬀects, either direct or indirect, of IL-17B in
endothelial cells and to examine the eﬃcacy of this cytokine
to impact on angiogenesis using in vivo models. Thus, initial
data suggests that IL-17B may hold potential as an anti-
angiogenic therapeutic; however, the high concentrations
needed to bring about any inhibition and how these would
be tolerated in vivo must also be considered in future
studies.
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